

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**

### **宜明昂科生物醫藥技術（上海）股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1541)**

## **CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE**

The board (the “**Board**”) of directors (“**Directors**”, each a “**Director**”) of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (the “**Company**”) hereby announces that Ms. Fu Dawei (付大偉), a non-executive Director, and Dr. Kendall Arthur Smith, an independent non-executive Director, were appointed as a member of the nomination committee of the Board (the “**Nomination Committee**”), both with effect from June 30, 2025.

After the above changes, the Nomination Committee consists of one executive Director, one non-executive Director and three independent non-executive Directors, namely, Dr. Tian Wenzhi (田文志) (chairperson of the Nomination Committee), Ms. Fu Dawei (付大偉), Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat (楊志達).

The above changes were made in response to the amendments to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Corporate Governance Code as set out in Appendix C1 to the Listing Rules, which will come into effect on July 1, 2025. The Board is convinced that implementing these changes could strengthen the effectiveness and diversity of the Board and the Nomination Committee, and further enhance the level of corporate governance practices of the Company as a whole.

The Board would like to express its warm welcome to Ms. Fu Dawei (付大偉) and Dr. Kendall Arthur Smith in their new roles in the Nomination Committee.

By order of the Board  
**ImmuneOnco Biopharmaceuticals (Shanghai) Inc.**  
宜明昂科生物醫藥技術（上海）股份有限公司  
**Tian Wenzhi**  
*Chairman and Executive Director*

Shanghai, the PRC, June 30, 2025

*As at the date of this announcement, the Board of Directors comprises (i) Dr. Tian Wenzhi, Mr. Li Song, Ms. Guan Mei and Mr. Zhang Ruliang as executive Directors; (ii) Dr. Xu Cong and Ms. Fu Dawei as non-executive Directors; and (iii) Dr. Zhenping Zhu, Dr. Kendall Arthur Smith and Mr. Yeung Chi Tat as independent non-executive Directors.*